<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725634</url>
  </required_header>
  <id_info>
    <org_study_id>P05538</org_study_id>
    <nct_id>NCT00725634</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma</brief_title>
  <acronym>P05538</acronym>
  <official_title>A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and&#xD;
      recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed&#xD;
      or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the&#xD;
      safety, tolerability and DLTs of AV-299 in combination with erlotinib in patients with&#xD;
      relapsed or refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity and Recommended Phase 2 dose</measure>
    <time_frame>Following 4 weeks of treatment</time_frame>
    <description>Assessment of any dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of AV-299, and erlotinib (for subjects enrolled in the Phase 1b only).</measure>
    <time_frame>Cycle 1: Day 1-4, Day 8 Cycle 2: Day 1, Day 8 Cycle 3: Day 1 Cycle 4: Day 8-14 Subsequent Cycles to Cycle 52: Day 1 End of Treatment Visit 1-Month and 2-Month Follow-Up Visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effects of AV-299 and combination of AV-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.</measure>
    <time_frame>Screening Cycle 1: Day 1-4, Day 8 Cycle 2: Day 1, Day 8-14 Cycle 4: Day 8-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the preliminary antineoplastic activity of AV-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of AV 299 in combination with erlotinib in subjects with advanced solid tumor.</measure>
    <time_frame>Advanced solid tumors and lymphoma, every 8 weeks through Cycle 29, and approximately every 12 weeks thereafter. Subjects with multiple myeloma will undergo disease assessment at screening and approximately every 4 weeks after Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the effect of AV-299 and of the combination of AV-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.</measure>
    <time_frame>Cycle 1: Day 1-4 Cycle 4: Day 8-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess dosing schedules of AV-299 (e.g. every 2-week and every 3-week schedules).</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability of the RP2D of AV-299 in expansion cohort(s).</measure>
    <time_frame>Throughout the expansion cohorts</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <condition>Lymphomas</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>AV-299 Dose Escalation Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-299 in combination with erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV-299</intervention_name>
    <description>AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.</description>
    <arm_group_label>AV-299 Dose Escalation Arm</arm_group_label>
    <other_name>Formerly SCH 900105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV-299 + erlotinib</intervention_name>
    <description>AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.</description>
    <arm_group_label>AV-299 in combination with erlotinib</arm_group_label>
    <other_name>Formerly SCH 900105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of an advanced solid tumor malignancy or lymphoma (non-Hodgkin's or&#xD;
             Hodgkin's lymphoma).&#xD;
&#xD;
          -  Histological or cytological evidence of malignancy.&#xD;
&#xD;
          -  Advanced malignancy, metastatic or unresectable, that has recurred or progressed&#xD;
             following standard therapy or failed standard therapy; or for which no standard&#xD;
             therapy currently exists, or for which subject is not a candidate for, or is unwilling&#xD;
             to undergo, standard therapy.&#xD;
&#xD;
          -  Disease that is currently not amenable to curative surgical intervention.&#xD;
&#xD;
          -  ECOG performance status of 0-1. Subjects with performance status of 2 will be&#xD;
             considered only after discussion between the investigator and medical monitor.&#xD;
&#xD;
          -  18 years or older, of either sex, and of any race.&#xD;
&#xD;
          -  Subject (and/or parent/guardian for subject who otherwise is unable to provide&#xD;
             independent consent, if acceptable to and approved by the site and/or site's IRB) must&#xD;
             be willing to give written informed consent and be able to adhere to dose and visit&#xD;
             schedules.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have negative pregnancy test within 5&#xD;
             days prior to first dose of study drug.&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects whose sexual partners are&#xD;
             of childbearing potential must agree to abstain from sexual intercourse or to use an&#xD;
             effective method of contraception during the study and for 60 days after the last dose&#xD;
             of AV-299 (formerly SCH 900105). Examples of effective methods of contraception&#xD;
             include, but are not limited to, oral contraceptives or double barrier methods such as&#xD;
             condom plus spermicide or condom plus diaphragm.&#xD;
&#xD;
          -  Adequate hematologic function as evidenced by Hg ≥ 9g/dL, WBC ≥ 3000 per mm3, ANC ≥&#xD;
             1500 per mm3 and platelet count ≥ 100,000 per mm3.&#xD;
&#xD;
          -  Adequate hepatic function as evidenced by a serum bilirubin level ≤1.5 × ULN (except&#xD;
             with known Gilbert's Syndrome) and&#xD;
&#xD;
          -  For subjects in the dose-escalation cohorts and the Phase 1b evaluation of AV-299&#xD;
             (formerly SCH 900105) in combination with erlotinib:&#xD;
&#xD;
             -- Serum AST/ALT levels ≤3 × ULN for the reference laboratory&#xD;
&#xD;
          -  For subjects in the RP2D safety expansion cohort:&#xD;
&#xD;
               -  Without known hepatic metastasis serum AST/ALT levels ≤3 × ULN for the reference&#xD;
                  laboratory&#xD;
&#xD;
               -  With known hepatic metastasis serum AST/ALT levels ≤5 × ULN.&#xD;
&#xD;
               -  Adequate renal function as evidenced by a serum creatinine level ≤ 1.5 × ULN or a&#xD;
                  calculated creatinine clearance &gt; 60 mL/min.&#xD;
&#xD;
               -  Adequate coagulation function as evidenced by PTT ≤ 1.5 × ULN and INR ≤ 1.5 × ULN&#xD;
&#xD;
               -  Recovery from the effects of any prior surgery, radiotherapy, or systemic&#xD;
                  antineoplastic therapy.&#xD;
&#xD;
               -  Subjects with abnormal liver function tests (LFTs) who have not been screened for&#xD;
                  Hepatitis B or C within the past 6 months prior to study enrollment, will need to&#xD;
                  be screened for Hepatitis B and C and can only be enrolled if the screening is&#xD;
                  negative.&#xD;
&#xD;
        Diagnosis and Main Criteria for Inclusion for the Multiple Myeloma Exploratory Cohort&#xD;
        Subjects to be Included&#xD;
&#xD;
          -  Diagnosis of symptomatic relapsed or refractory multiple myeloma. Note: For relapsed&#xD;
             disease, subject must have PD after having achieved at least stable disease for ≥ 1&#xD;
             cycle of treatment to ≥ 1 prior regimen. For refractory disease, subject must have&#xD;
             documented evidence of PD during or within 60 days (measured from the end of the last&#xD;
             cycle) of completing treatment with the last anti-myeloma drug regimen used just prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Measurable disease assessed by one of the following:&#xD;
&#xD;
               -  Serum monoclonal protein ≥ 1.0 g/dL by protein electrophoresis;&#xD;
&#xD;
               -  &gt; 200 mg of monoclonal protein in the urine on 24 hour electrophoresis;&#xD;
&#xD;
               -  Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum&#xD;
                  immunoglobulin kappa to lambda free light chain ratio; or,&#xD;
&#xD;
               -  Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease). Note: All above&#xD;
                  evaluations, for which there are measurable results at screening, will be&#xD;
                  repeated as indicated in the visit schedule and the schedule of assessments, with&#xD;
                  the exception of bone marrow plasmacytosis. Bone marrow plasmacytosis will be&#xD;
                  repeated for disease/response assessment according to the visit schedule and the&#xD;
                  schedule of assessments if it is the only measurable result at screening. If both&#xD;
                  serum and urine M-proteins are present, both must be followed in order to&#xD;
                  evaluate response.&#xD;
&#xD;
          -  At least 2 prior therapies&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  18 years or older, of either sex, and of any race.&#xD;
&#xD;
          -  Subject (and/or parent/guardian for subject who otherwise is unable to provide&#xD;
             independent consent, if acceptable to and approved by the site and/or site's IRB) must&#xD;
             be willing to give written informed consent and be able to adhere to dose and visit&#xD;
             schedules.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have negative pregnancy test within 5&#xD;
             days prior to first dose of study drug.&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects whose sexual partners are&#xD;
             of childbearing potential must agree to abstain from sexual intercourse or to use an&#xD;
             effective method of contraception during the study and for 60 days after the last dose&#xD;
             of AV-299 (formerly SCH 900105). Examples of effective methods of contraception&#xD;
             include, but are not limited to, oral contraceptives or double barrier methods such as&#xD;
             condom plus spermicide or condom plus diaphragm.&#xD;
&#xD;
          -  Adequate hematologic function as evidenced by Hg ≥ 9g/dL, ANC ≥ 1000 per mm3, and&#xD;
             platelet count ≥ 50,000 per mm3. Screening platelet count should be independent of&#xD;
             platelet transfusions for ≥ 2 weeks.&#xD;
&#xD;
          -  Adequate hepatic function as evidenced by a serum bilirubin level ≤ 1.5 × ULN (except&#xD;
             with known Gilbert's Syndrome) and serum AST and ALT levels ≤ 3 × ULN.&#xD;
&#xD;
          -  Adequate renal function as evidenced by a serum creatinine level ≤ 3.0 mg/dL.&#xD;
&#xD;
          -  Adequate coagulation function as evidenced by PTT ≤ 1.5 × ULN and INR ≤ 1.5 × ULN.&#xD;
&#xD;
          -  All previous cancer chemotherapy, including radiation, hormonal therapy, and surgery,&#xD;
             must have been discontinued ≥ 2 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Subjects with abnormal liver function tests (LFTs) who have not been screened for&#xD;
             Hepatitis B or C within the past 6 months prior to study enrollment, will need to be&#xD;
             screened for Hepatitis B and C and can only be enrolled if the screening is negative.&#xD;
&#xD;
          -  Subject willing to provide blood and if feasible, bone marrow samples for research&#xD;
             purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are breast-feeding, pregnant, or intend to become pregnant.&#xD;
&#xD;
          -  Subjects with primary CNS malignancy or symptomatic CNS metastases, with the exception&#xD;
             that subjects with glioblastoma multiforme may be enrolled in the RP2D Safety&#xD;
             Expansion Cohort and in the Phase 1b evaluation of AV-299 (formerly SCH 900105) in&#xD;
             combination with erlotinib. Subjects with treated brain metastases that have remained&#xD;
             stable for at least 3 months without steroids are allowed. Subjects with signs or&#xD;
             symptoms or history of brain metastasis must have a CT or MRI scan of the brain within&#xD;
             1 month prior to the first dose of study drug. Subjects with spinal cord or nerve root&#xD;
             compression who have completed treatment at least 4 weeks prior to the first dose of&#xD;
             study drug and are stable without steroid treatment for at least 1 week prior to the&#xD;
             first dose of study drug are allowed. Subjects with leptomeningeal metastases are not&#xD;
             allowed.&#xD;
&#xD;
          -  Hematologic malignancies other than lymphoma&#xD;
&#xD;
          -  Any of the following within 6 months prior to administration of study drug:&#xD;
&#xD;
        Myocardial infarction (MI), severe /unstable angina pectoris, coronary/peripheral artery&#xD;
        bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient&#xD;
        ischemic attack or seizure disorder.&#xD;
&#xD;
          -  Serious and/or symptomatic active infection within 14 days prior to first dose of&#xD;
             study drug. Subjects who have asymptomatic or mild infection and taking a short course&#xD;
             of antibiotics (ie, UTI, bronchitis) may be allowed after discussion with the medical&#xD;
             monitor.&#xD;
&#xD;
          -  Baseline QTc interval as follows per Bazett's formula: Females &gt; 470 msec; Males &gt; 450&#xD;
             msec.&#xD;
&#xD;
          -  Persistent, unresolved CTCAE v3.0 Grade 2 or higher drug-related toxicity (except&#xD;
             alopecia, erectile dysfunction, hot flashes, and decreased libido) associated with&#xD;
             previous treatment.&#xD;
&#xD;
          -  Inadequate recovery from any prior surgical procedure or major surgical procedure&#xD;
             performed within 4 weeks prior to administration of first dose or major surgery within&#xD;
             3 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Any other medical or psychiatric condition that, in the opinion of the investigator,&#xD;
             might interfere with the subject's participation in the trial or interfere with the&#xD;
             interpretation of trial results.&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV) infection or a known HIV-related malignancy.&#xD;
&#xD;
          -  Known active hepatitis B or C.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of AV-299 (formerly SCH 900105).&#xD;
&#xD;
          -  Radiotherapy within 3 weeks prior to first study drug administration.&#xD;
&#xD;
          -  Inability to comply with the protocol requirements or participation in any other&#xD;
             clinical study.&#xD;
&#xD;
          -  Any medications listed in the table on &quot;Prohibited Medications&quot;.&#xD;
&#xD;
          -  Active alcohol abuse.&#xD;
&#xD;
          -  Stem cell/bone marrow transplant within 6 months of first dose of study drug.&#xD;
&#xD;
        Additional Exclusion Criteria for Subjects Enrolled in the Phase 1b Evaluation of AV-299&#xD;
        (formerly SCH 900105) in Combination with Erlotinib:&#xD;
&#xD;
          -  Inability to take oral medications&#xD;
&#xD;
          -  Grade 2 or higher diarrhea at baseline, or inflammatory bowel disease&#xD;
&#xD;
          -  Any gastrointestinal disorder that may interfere with the absorption of oral&#xD;
             medications&#xD;
&#xD;
          -  Acute onset of new or progressive pulmonary symptoms, such as dyspnea, cough or fever&#xD;
             within 4 weeks prior to first study treatment, or diagnosis of interstitial lung&#xD;
             disease (ILD)&#xD;
&#xD;
        Exclusion for the Multiple Myeloma Exploratory Cohort&#xD;
&#xD;
          -  Women who are breast-feeding, pregnant, or intend to become pregnant.&#xD;
&#xD;
          -  Active malignancy of any kind requiring or likely to require treatment within the next&#xD;
             12 months, with the exception of basal cell skin cancer, in situ cervical cancer, in&#xD;
             situ breast cancer and asymptomatic prostate cancer.&#xD;
&#xD;
          -  Any of the following prior to first dose of study drug: POEMS (polyneuropathy,&#xD;
             organomegaly, endocrinopathy, monoclonal protein, and skin changes), plasma cell&#xD;
             leukemia, Waldenstrom's macroglobulinemia.&#xD;
&#xD;
          -  Any of the following within 6 months prior to administration of study drug:&#xD;
&#xD;
        Myocardial infarction (MI), severe /unstable angina pectoris, coronary/peripheral artery&#xD;
        bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient&#xD;
        ischemic attack or seizure disorder.&#xD;
&#xD;
          -  Serious and/or symptomatic active infection within 14 days prior to first dose of&#xD;
             study drug. Subjects who have asymptomatic or mild infection and taking a short course&#xD;
             of antibiotics (ie, UTI, bronchitis) may be allowed after discussion with the medical&#xD;
             monitor.&#xD;
&#xD;
          -  Baseline QTc interval as follows per Bazett's formula: Females &gt; 470 msec; Males &gt; 450&#xD;
             msec.&#xD;
&#xD;
          -  Persistent, unresolved CTCAE v3.0 Grade 2 or higher drug-related toxicity (except&#xD;
             alopecia, erectile dysfunction, hot flashes, and decreased libido) associated with&#xD;
             previous treatment.&#xD;
&#xD;
          -  Inadequate recovery from any prior surgical procedure or major surgical procedure&#xD;
             performed within 4 weeks prior to administration of first dose or major surgery within&#xD;
             3 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Any other medical or psychiatric condition that, in the opinion of the investigator,&#xD;
             might interfere with the subject's participation in the trial or interfere with the&#xD;
             interpretation of trial results.&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV) infection or a known HIV-related malignancy.&#xD;
&#xD;
          -  Known active hepatitis B or C.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of AV-299 (formerly SCH 900105).&#xD;
&#xD;
          -  Radiotherapy within 3 weeks prior to first study drug administration, except when used&#xD;
             as palliative treatment for pain control.&#xD;
&#xD;
          -  Inability to comply with the protocol requirements or participation in any other&#xD;
             clinical study.&#xD;
&#xD;
          -  Any medications listed in the table on &quot;Prohibited Medications&quot;.&#xD;
&#xD;
          -  Active alcohol abuse.&#xD;
&#xD;
          -  Maintenance steroid therapies of &gt; 20 mg/day prednisone, &gt; 4 mg/day dexamethasone, &gt;&#xD;
             80 mg/day hydrocortisone, or equivalent.&#xD;
&#xD;
        NOTE: Maintenance steroid therapies of ≤ 20 mg/day prednisone, ≤ 4 mg/day dexamethasone, ≤&#xD;
        80 mg/day hydrocortisone, or equivalent are allowed provided that the subject is on a&#xD;
        stable dose for at least 2 weeks prior to first dose of study drug or the dose has not been&#xD;
        adjusted upwards in the 2 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Prior therapy involving anti-HGF antibody or c-Met small molecule inhibitor.&#xD;
&#xD;
          -  Allogeneic stem cell/bone marrow transplant within 12 months of first dose of study&#xD;
             drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Komarnitsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>AVEO Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site 2</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 1</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms,</keyword>
  <keyword>Lymphoma,</keyword>
  <keyword>Multiple Myeloma,</keyword>
  <keyword>Neoplasms, Plasma Cell,</keyword>
  <keyword>Neoplasms by Histologic Type,</keyword>
  <keyword>Lymphoproliferative Disorders,</keyword>
  <keyword>Lymphatic Diseases, Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases Hemostatic Disorders</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Paraproteinemias</keyword>
  <keyword>Blood Protein Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Protein Kinase Inhibitors</keyword>
  <keyword>Enzyme Inhibitors,</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

